All In Biotech

Drug Trial Radar · NCT02719574

Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation

A Phase 1/2, Multicenter, Open-label Study of FT-2102 as a Single Agent and in Combination With Azacitidine or Cytarabine in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome With an IDH1 Mutation

Last checked: Nov 20, 2026Latest source record: Jun 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

336

Actual

Start

Apr 30, 2016

Primary completion

Dec 28, 2023

Study completion Jan 24, 2024

Sponsor

Lead sponsor
Forma Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Mar 25, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 1/2 study will evaluate the safety, efficacy, PK, and PD of FT-2102 (olutasidenib) as a single agent or in combination with azacitidine or cytarabine. The Phase 1 stage of the study is split into 2 distinct parts: a dose escalation part, which will utilize an open-label design of FT-2102 (olutasidenib) (single agent) and FT-2102 (olutasidenib) + azacitidine (combination agent) administered via one or more intermittent dosing schedules followed by a dose expansion part. The dose expansion part will enroll patients in up to 5 expansion cohorts, exploring single-agent FT-2102 (olutasidenib) activity as well as combination activity with azacitidine or cytarabine. Following the completion of the relevant Phase 1 cohorts, Phase 2 will begin enrollment. Patients will be enrolled across 8 different cohorts, examining the effect of FT-2102 (olutasidenib) (as a single agent) and FT-2102 (olutasidenib) + azacitidine (combination) on various AML/MDS disease states.

Conditions

  • Acute Myeloid Leukemia
  • Acute Myelogenous Leukemia
  • Myelodysplastic Syndrome

Interventions

  • FT-2102 (olutasidenib)Drug

    FT-2102 (olutasidenib) will be supplied as 50 mg or 150 mg capsules and will be administered per the protocol defined frequency and dose level

  • AzacitidineDrug

    azacitidine will be administered per site's standard of care

  • CytarabineDrug

    low-dose cytarabine will be administered per site's standard of care

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: Phase 1: From start of drug administration (Day 1) up to 28 days after last dose of study drug (up to 82 months)
  2. Phase 1: Number of Participants With Change From Baseline in Clinically Significant Abnormal Laboratory ValuesTime frame: Phase 1: From Baseline up to 28 days after last dose of study drug (up to 82 months)
  3. Phase 1: Number of Participants With Change From Baseline in Clinically Significant Abnormal Electrocardiogram (ECG)Time frame: Phase 1: From Baseline up to 28 days after last dose of study drug (up to 82 months)
  4. Phase 2, Cohort 1: Percentage of Participants With Complete Remission (CR) Plus Complete Remission With Partial Hematological Recovery (CRh) for Acute Myeloid Leukemia Assessed by Investigator Based on International Working Group (IWG) Response CriteriaTime frame: Phase 2: up to 3 weeks post last dose of study drug or until the introduction of new anticancer therapy, whichever is earlier (up to 82 months)
  5. Phase 2, Cohort 3, 4, 5, 6, 7, 8: Percentage of Participants With CR Plus CRh for Acute Myeloid Leukemia Assessed by Investigator Based on IWG Response CriteriaTime frame: Phase 2: up to 3 weeks post last dose of study drug or until the introduction of new anticancer therapy, whichever is earlier (up to 82 months)
  6. Phase 2, Cohort 4 and 5: Percentage of Participants With CR for MDS Assessed by IWG Response CriteriaTime frame: Phase 2: up to 3 weeks post last dose of study drug or until the introduction of new anticancer therapy, whichever is earlier (up to 82 months)
  7. Phase 2, Cohort 2: Four-month Relapse Free Survival (RFS) RateTime frame: Phase 2: From the date of first dose until relapse or death from any cause, whichever occurs first (up to 4 months)

Locations

60 sites in 9 countries. Site status is shown where the registry gives one.

  • UCLA Medical Center

    Los Angeles, California

  • UC Davis Comprehensive Cancer Center

    Sacramento, California

  • Yale University

    New Haven, Connecticut

  • University of Miami

    Miami, Florida

  • Emory Winship Cancer Institute

    Atlanta, Georgia

  • Northwestern University Feinberg School of Medicine

    Chicago, Illinois

  • University of Maryland Greenebaum Cancer Center

    Baltimore, Maryland

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Roswell Park Cancer Institute

    Buffalo, New York

  • New York Medical College

    Hawthorne, New York

  • Columbia University Medical Center

    New York, New York

  • Cornell University Weill Medical College

    New York, New York

  • Duke University Medical Center

    Durham, North Carolina

  • The Ohio State University

    Columbus, Ohio

  • Oregon Health & Science University

    Portland, Oregon

  • Sarah Cannon Research Institute - Tennessee Oncology

    Nashville, Tennessee

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • MD Anderson Cancer Center

    Houston, Texas

  • Box Hill Hospital, Monash University and Eastern Health Clinical School

    Box Hill, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia

  • The Alfred Hospital

    Melbourne, Victoria, Australia

  • Victoria Cancer Care Center

    Parkville, Victoria, Australia

  • Sir Charles Gairdner Hospital

    Nedlands, Western Australia, Australia

  • Princess Margaret Hospital

    Toronto, Ontario, Canada

  • Service d'Hématologie Clinique, Hôpital Avicenne-APHP-Université Paris

    Bobigny, France

  • Assistance Publique Hopitaux de Marseille (AP-HM) - Hopital Nord

    Marseille, France

  • Centre Hospitalier Universitaire Nantes

    Nantes, France

  • Hôpital Saint-Louis

    Paris, France

  • Hopitaux Universitaires Est Parisien Hopital Saint-Antoine

    Paris, France

  • Centre Hospitalier Universitaire (CHU) Bordeaux - Hospitaux du Haut Leveque

    Pessac, France

  • Centre Hospitalier Lyon Sud

    Pierre-Bénite, France

  • University Hospital of Rennes

    Rennes, France

  • Institut Universitaire du Cancer Toulouse - Oncopole

    Toulouse, France

  • Centre Hospitalier Universitaire de Nancy - Hopital Brabois

    Vandœuvre-lès-Nancy, France

  • Institut de Cancérologie Gustave Roussy

    Villejuif, France

  • Staedtisches Klinikum Braunschweig gGmbH

    Braunschweig, Germany

  • Universitaetsklinikum Giessen und Marburg GmbH - Klinik fuer Innere Medizin

    Giessen, Germany

  • Landeszentrum fuer Zell- und Gentherapie

    Halle, Germany

  • Universitätsklinikum Münster Medizinische Klinik A, Hämatologie, Hämostaseologi

    Münster, Germany

Showing 40 of 60 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.